Dr Reddy’s began as an active pharmaceutical ingredients (API) manufacturer in 1984, producing high-quality APIs for the Indian domestic market. In 1987, the company started its formulations operations and, after becoming a force to reckon with in the Indian formulations market, went international in 1991.
Dr Reddy’s today is more than a 200-million dollar venture with presence in almost all major therapeutic areas. The company is committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products, Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company’s major therapeutic focus is on gastrointestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets for Dr Reddy’s include India, USA, Russia-CIS and Europe, apart from other select geographies within emerging markets.
Recently, Dr Reddy’s deepened its focus into the rural markets in India to ensure the expansion of its reach. In this initiative, the company collaborated with its CSR wing, Dr Reddy’s Foundation to reach the millions who are still away from effective treatment and availability of the right medicines.
Dr Reddy: Providing affordable and innovative healthcare
|2013||Features in ‘Forbes Asia Fab 50 companies’ list at a special Forbes Asia Fab 50 awards ceremony held in China|
|2011||Receives Pharmexcil Award (Gold Prize) for ‘Outstanding Export Performance for 2010–11’ in the ‘Large Scale Industry’ category|
|2009||Announces Strategic Alliance with GlaxoSmithKline for emerging markets|
|2007||Launches Reditux™ (Rituximab) – the world’s first biosimilar of a monoclonal antibody|
|2005||Acquires Roche’s API business in Mexico|